Alzheimer’s disease could be slowed by boosting a certain protein in the brain, researchers say
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The University of Cincinnati researchers and an Alzheimer's Association expert weigh in.
Study shows Alzheimer’s drugs may boost protein, not just lower amyloid
Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain,
Boosting brain protein levels may slow decline from Alzheimer's
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.
Alzheimer's Decline May Be Slowed by Protein Boost
"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of clumped up Aβ42. Once in amyloid, Aβ42 no longer works (the plaques can be viewed as a tombstone of Aβ42)."
Study finds Alzheimer's drugs might boost healthy protein in brain
Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.
Boosting brain protein levels may slow Alzheimer’s progression
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s patients. This finding challenges the long-held belief that reducing amyloid plaques is the best way to treat the disease.
Medical News Today1d
New study challenges amyloid-beta theory on cause for Alzheimer's disease
We discovered that what keeps people with amyloid plaques cognitively normal is (not) the level of the plaques in the brain ...
McKnight's Long-Term Care News6h
Study: Amyloid-beta, tau buildup affect brain activity before Alzheimer’s shows up
A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...
Amyloid Plaques May Not Cause Alzheimer’s: New Research Challenges Decades-Old Theories
A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...
GlobalData on MSN13d
Qiagen and Lilly team up for Alzheimer’s genotype test
The QIAstat-Dx in-vitro diagnostic will detect the apolipoprotein E (APOE) genotypes to help diagnose Alzheimer’s disease.
Study uncovers critical biomarker differences, advocates for more inclusive Alzheimer's diagnostics
The Emory Goizueta Brain Health Institute (GBHI) has prioritized involving African American volunteers in its research, ...
Endocrinology Advisor5d
Caffeine Intake Might Protect Against Alzheimer Disease, Mild Cognitive Impairment
Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.